Hormone Resistant Prostate Cancer Terminated Phase 2 Trials for Prednisone (DB00635)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02844582Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTreatment
NCT01469338Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With DocetaxelSupportive Care
NCT01145508Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTreatment